Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

How to assess kidney function in oncology patients

J. Malyszko, MW. Lee, G. Capasso, P. Kulicki, J. Matuszkiewicz-Rowinska, P. Ronco, P. Stevens, P. Tesarova, D. Viggiano, A. Capasso

. 2020 ; 97 (5) : 894-903. [pub] 20200303

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21020592

Assessment of kidney function in oncology patients is a fundamental factor in profiling the survival risk, determining the appropriate dose of chemotherapeutic drugs, and defining a patient eligibility for clinical trials with novel agents. Both overestimation and underestimation of kidney function may affect the treatment efficacy and outcomes. Overestimation may lead to overdosing or inappropriate agent selection and the corresponding toxicity, whereas underestimation may be responsible for underdosing or inappropriate agent exclusion and subsequent treatment failure. This is of utmost importance in patients with cancer. Evaluation of kidney function is not only limited to the estimation of glomerular filtration rate or creatinine clearance. An accurate assessment of kidney function is advisable to reduce variability in decision making and ultimately the therapeutic outcomes of toxicity and clinical benefit. Therefore, additional studies are needed to investigate the validity of currently used formulas estimating kidney function in this population as well as their applicability to traditional chemotherapy, novel targeted therapies, and immunotherapies. Because of rapid discovery and development of new cancer agents, a reliable and comprehensive manner to screen for potential nephrotoxicity is critically important. As kidney function not only is limited to glomerular filtration rate changes but also involves tubular and even vascular dysfunction, urinalysis and kidney imaging studies should also be considered before therapeutic decisions are taken. However, several questions remain regarding these new technologies such as kidney-on-a-chip systems for the assessment of kidney function and injury, particularly in oncology, and it has yet to be implemented in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020592
003      
CZ-PrNML
005      
20210830102229.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2019.12.023 $2 doi
035    __
$a (PubMed)32229094
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malyszko, Jolanta $u Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland. Electronic address: jolmal@poczta.onet.pl
245    10
$a How to assess kidney function in oncology patients / $c J. Malyszko, MW. Lee, G. Capasso, P. Kulicki, J. Matuszkiewicz-Rowinska, P. Ronco, P. Stevens, P. Tesarova, D. Viggiano, A. Capasso
520    9_
$a Assessment of kidney function in oncology patients is a fundamental factor in profiling the survival risk, determining the appropriate dose of chemotherapeutic drugs, and defining a patient eligibility for clinical trials with novel agents. Both overestimation and underestimation of kidney function may affect the treatment efficacy and outcomes. Overestimation may lead to overdosing or inappropriate agent selection and the corresponding toxicity, whereas underestimation may be responsible for underdosing or inappropriate agent exclusion and subsequent treatment failure. This is of utmost importance in patients with cancer. Evaluation of kidney function is not only limited to the estimation of glomerular filtration rate or creatinine clearance. An accurate assessment of kidney function is advisable to reduce variability in decision making and ultimately the therapeutic outcomes of toxicity and clinical benefit. Therefore, additional studies are needed to investigate the validity of currently used formulas estimating kidney function in this population as well as their applicability to traditional chemotherapy, novel targeted therapies, and immunotherapies. Because of rapid discovery and development of new cancer agents, a reliable and comprehensive manner to screen for potential nephrotoxicity is critically important. As kidney function not only is limited to glomerular filtration rate changes but also involves tubular and even vascular dysfunction, urinalysis and kidney imaging studies should also be considered before therapeutic decisions are taken. However, several questions remain regarding these new technologies such as kidney-on-a-chip systems for the assessment of kidney function and injury, particularly in oncology, and it has yet to be implemented in clinical practice.
650    _2
$a kreatinin $7 D003404
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a lidé $7 D006801
650    12
$a ledviny $7 D007668
650    _2
$a vyšetření funkce ledvin $7 D007677
650    12
$a nádory $x farmakoterapie $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Lee, Michael W $u Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, Texas, USA
700    1_
$a Capasso, Giovambattista $u Department of Translational Medical Sciences, University Luigi Vanvitelli, Naples, Italy; Biogem Institute, Ariano Irpino, Italy
700    1_
$a Kulicki, Pawel $u Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland
700    1_
$a Matuszkiewicz-Rowinska, Joanna $u Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland
700    1_
$a Ronco, Pierre $u Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, Hôpital Tenon, Paris, France; Assistance Publique-Hôpitaux de Paris, Department of Nephrology, Hôpital Tenon, Paris, France
700    1_
$a Stevens, Paul $u East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, UK
700    1_
$a Tesarova, Petra $u Department of Oncology, Charles University, Prague, Czech Republic
700    1_
$a Viggiano, Davide $u Department of Translational Medical Sciences, University Luigi Vanvitelli, Naples, Italy; Biogem Institute, Ariano Irpino, Italy
700    1_
$a Capasso, Anna $u Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, Texas, USA
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 97, č. 5 (2020), s. 894-903
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32229094 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102230 $b ABA008
999    __
$a ok $b bmc $g 1691215 $s 1141038
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 97 $c 5 $d 894-903 $e 20200303 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options